Critical Insights From Inari Medical Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Inari Medical (NASDAQ:NARI) has seen diverse analyst ratings over the past quarter, with recent actions including maintaining, lowering, and raising ratings and price targets. The average 12-month price target is now $67.5, down from $73.00, indicating a 7.53% decrease. Inari Medical's financial performance shows strong growth and profitability, with a revenue growth rate of 31.35% as of September 30, 2023, and a net margin of 2.5%. The company's ROE and ROA exceed industry averages, and it maintains a low debt-to-equity ratio of 0.07.
February 29, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Inari Medical has received mixed analyst ratings, with a decrease in the average price target to $67.5. The company's financial performance is strong, with significant revenue growth and profitability.
The mixed analyst ratings and the decrease in the average price target may create uncertainty in the short term. However, Inari Medical's strong financial performance, including high revenue growth and profitability, could mitigate negative impacts and provide a stable outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100